This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Recent talks from Boehringer Ingelheim standalone meetings
The Conversations in Oncology in Mexico was the first of its kind to be held in Latin America and brought together 170 doctors from across Latin and South America in Cancun, Mexico, in October 2015. A unique ‘joint venture’ between the well-respected national “Debates in Cancer” (already in its 5th year) and the Boehringer Ingelheim “Conversations in Oncology” initiative, this event gave the audience the chance to attend both plenary sessions and smaller workshops, discussing case studies and scientific questions.
To view slides from the various presentation, simply click on your file of choice below.
Lung Cancer: Molecular Biology 2015
Next-Generation Sequencing/Biomarkers: Advanced Technology
State of the Art in Urothelial Cancers
Management of Brain Metastases and Oligometastases in Non–Small Cell Lung Cancer (NSCLC)
Novel Advances in the Management of Squamous Cell Carcinoma of the Head and Neck
Challenges in the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Impact of Overall Survival in Advanced NSCLC EGFR+
Best Practices in Pathology: Are We There Yet?
Treatment of Wild Type Non-Small Cell Lung Cancer: 2015
Immunotherapeutic Approaches in the Treatment of NSCLC
State of the Art Colorectal Cancer (CRC)
Targeting Angiogenesis in NSCLC
The Story of BIBF1120 – Nintedanib*–Vargatef®
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue